13F Pro quality score
Rank #2,222 of 2,856
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
CRYO CELL INTERNATIONAL INC (CCEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCEL at 35.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,222 of 2,856 stocks — the bottom half of the AI-ranked universe. CCEL scores in the top quartile across earnings quality (79.5). Areas of concern include revenue scale (7.1) and institutional flow (9.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), CRYO CELL INTERNATIONAL INC reports quarterly revenue of $7.8M, net income of $1.3M, an operating margin of 28.0%. CCEL trades on the NYSE exchange and files with the SEC under CIK 862692. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRYO CELL INTERNATIONAL INC directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 862692 →